Beacon Pointe Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Beacon Pointe Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Buy	+836	New	+$183K	﹤0.01%	1808

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Beacon Pointe Advisors's JAZZ Position: Q2 2026 in Review

Beacon Pointe Advisors opened a new position in Jazz Pharmaceuticals (JAZZ) in Q2 2026: 836 shares worth $201K. The stake represents ﹤0.01% of the portfolio and ranks #1808 among its holdings.

641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Beacon Pointe Advisors held 836 shares of Jazz Pharmaceuticals worth $201K as of Q2 2026.
Jazz Pharmaceuticals was a new Beacon Pointe Advisors position in Q2 2026.
Jazz Pharmaceuticals made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1808 holding.
641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.